Glaucoma Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies - SPARC, Tear Clear, Santen Pharmaceutical, Nicox Ophthalmics, Ocuphire Pharma, Kowa, Johnson & Johnson

The Glaucoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Glaucoma pipeline products will significantly revolutionize the Glaucoma market dynamics.

DelveInsight's "Glaucoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Glaucoma, historical and forecasted epidemiology as well as the Glaucoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Glaucoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Glaucoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Glaucoma Market Insights
https://www.delveinsight.com/report-store/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Glaucoma Overview
Glaucoma is a disease that damages the eye's optic nerve. It usually happens when fluid builds up in the front part of the eye. That extra fluid increases the pressure in eye, damaging the optic nerve. The condition is a leading cause of blindness for people over 60 years old. But blindness from glaucoma can often be prevented with early treatment.

Some of the key facts of the Glaucoma Market Report:
• The Glaucoma market size was valued at USD 4,466 Million in the year 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The total diagnosed prevalence of Glaucoma in 7MM was estimated to be 11,048,000 cases in 2021 and is expected to increase during the study period (2019-2032)
• The total diagnosed prevalent population of Open angle Glaucoma (OAG) and Close Angle Glaucoma in the US was estimated to be 3,119,031 cases and 346,559 cases in 2021 and is expected to increase during the study period (2019-2032)
• In the EU-5 region, the total diagnosed prevalence of Glaucoma was highest in Germany with 1,115,113 cases followed by Italy with 965,487 cases in 2021. Spain reported the least number of cases among EU-5 with 562,471 cases in 2021
• The total diagnosed prevalence of Glaucoma in the US was estimated to be 3,465,590cases in 2021 and is expected to increase during the study period (2019-2032)
• In February 2022, Santen Pharmaceutical Co., Ltd. was granted the marketing authorization for the PRESERFLO MicroShunt Glaucoma Drainage System Core Kit, an intraocular drainage device
• In May 2021, Glaukos Corporation entered into a new development and commercialization license agreement with Santen Pharmaceutical Co., Ltd. (Santen) for the PRESERFLO™ MicroShunt (development code: DE-128). The former company has also obtained exclusive commercialization rights for the MicroShunt in the United States, Australia, New Zealand, Canada, Brazil, Mexico, and the remainder of Latin America
• Key Glaucoma Companies: SPARC, Tear Clear, Santen Pharmaceutical, Nicox Ophthalmics, Ocuphire Pharma, Kowa, Johnson & Johnson Services, Inc., Alcon Inc., Glaukos Corporation, AbbVie Inc., and others
• Key Glaucoma Therapies: PDP-716, TC-002, Omidenepag isopropyl/DE-117, DE-130A, Sepetaprost (DE-126/ONO9054), NCX-470, Nyxol, K-232, and others
• The Glaucoma epidemiology based on gender analyzed that among the gender-specific prevalent cases, females are affected more with glaucoma than male

Get a Free sample for the Glaucoma Market Report -
https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Key benefits of the Glaucoma Market report:
1. Glaucoma market report covers a descriptive overview and comprehensive insight of the Glaucoma Epidemiology and Glaucoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Glaucoma market report provides insights on the current and emerging therapies.
3. Glaucoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Glaucoma market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Glaucoma market.

Download the report to understand which factors are driving Glaucoma epidemiology trends @ Glaucoma Epidemiological Insights
https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Glaucoma Market
The dynamics of the Glaucoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
"The mainstay of the treatment for Glaucoma is to improve quality of life. There are therapies that are undergoing investigational analysis for the same. Pharmaceutical giants like Santen, SPARC, Bausch and Lomb, and others have their candidates in the pipeline."

Glaucoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Glaucoma Epidemiology Segmentation:
The Glaucoma market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Glaucoma
• Prevalent Cases of Glaucoma by severity
• Gender-specific Prevalence of Glaucoma
• Diagnosed Cases of Episodic and Chronic Glaucoma
Glaucoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Glaucoma market or expected to get launched during the study period. The analysis covers Glaucoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Glaucoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Discover more about therapies set to grab major Glaucoma market share @ Glaucoma market forecast
https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Glaucoma Therapies and Key Companies
• PDP-716: SPARC
• TC-002: Tear Clear
• Omidenepag isopropyl/DE-117: Santen Pharmaceutical
• DE-130A: Santen Pharmaceutical
• Sepetaprost (DE-126/ONO9054): Santen Pharmaceutical
• NCX-470: Nicox Ophthalmics
• Nyxol: Ocuphire Pharma
• K-232: Kowa

Glaucoma Market Drivers
• Increasing prevalence of glaucoma
• Rich emerging Glaucoma pipeline
• Development of advanced anti-glaucoma medications
• Patients-friendly dosage regimes
• Rise in awareness

Scope of the Glaucoma Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Glaucoma Companies: SPARC, Tear Clear, Santen Pharmaceutical, Nicox Ophthalmics, Ocuphire Pharma, Kowa, Johnson & Johnson Services, Inc., Alcon Inc., Glaukos Corporation, AbbVie Inc., and others
• Key Glaucoma Therapies: PDP-716, TC-002, Omidenepag isopropyl/DE-117, DE-130A, Sepetaprost (DE-126/ONO9054), NCX-470, Nyxol, K-232, and others
• Glaucoma Therapeutic Assessment: Glaucoma current marketed and Glaucoma emerging therapies
• Glaucoma Market Dynamics: Glaucoma market drivers and Glaucoma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Glaucoma Unmet Needs, KOL's views, Analyst's views, Glaucoma Market Access and Reimbursement

Glaucoma Market Barriers
• Lack of ideal animal models for glaucoma
• Socioeconomic barriers
• Underdiagnosis of Glaucoma

Table of Contents
1. Glaucoma Market Report Introduction
2. Executive Summary for Glaucoma
3. SWOT analysis of Glaucoma
4. Glaucoma Patient Share (%) Overview at a Glance
5. Glaucoma Market Overview at a Glance
6. Glaucoma Disease Background and Overview
7. Glaucoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Glaucoma
9. Glaucoma Current Treatment and Medical Practices
10. Glaucoma Unmet Needs
11. Glaucoma Emerging Therapies
12. Glaucoma Market Outlook
13. Country-Wise Glaucoma Market Analysis (2019-2032)
14. Glaucoma Market Access and Reimbursement of Therapies
15. Glaucoma Market Drivers
16. Glaucoma Market Barriers
17. Glaucoma Appendix
18. Glaucoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

To know more about Glaucoma treatment, visit @ Glaucoma Medications https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Related Reports:
Glaucoma Pipeline https://www.delveinsight.com/report-store/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Glaucoma Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Glaucoma market. A detailed picture of the Glaucoma pipeline landscape is provided, which includes the disease overview and Glaucoma treatment guidelines.
Glaucoma Epidemiology https://www.delveinsight.com/report-store/glaucoma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Glaucoma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Glaucoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Related Reports By DelveInsight -

Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry
https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.